Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is an open -label, Multicenter Study to Assess the Safety, Tolerability,
Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with durvalumab in
patients advanced NSCLC who progressed following platinum-based chemotherapy.